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WHAT THIS PAPER ADDS 
 This paper is the first to calculate the substantially improved health outcomes that 
could be delivered from increasing the tobacco duty escalator in the UK. 
 Increasing the tobacco duty escalator on cigarettes from 2% to 5% above inflation 
could reduce smoking prevalence from an estimated 10% to around 6% in the UK, 
avoiding around 75,200 cases of disease in the next twenty years. 
 Increasing the tobacco duty escalator would also have a substantial impact on 
reducing costs to the NHS, social care and wider society.   
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ABSTRACT 
Introduction 
Taxing tobacco is one of the most effective ways to reduce smoking prevalence, mitigate its 
devastating consequential health harms, and progress towards a tobacco-free society. This 
study modelled the health and economic impacts of increasing the existing cigarette tobacco 
duty escalator (TDE) in the UK from the current 2% above consumer price inflation to 5%. 
Methods 
A two-stage modelling process was used. Firstly, a non-linear multivariate regression model 
was fitted to cross-sectional smoking data, creating longitudinal projections from 2015 to 
2035. Secondly, these projections were used to predict the future incidence, prevalence and 
cost of 17 smoking-related diseases using a Monte Carlo microsimulation approach. A 
sustained increase in the duty escalator was evaluated against a baseline of continuing 
historical smoking trends and the existing duty escalator. 
Results 
A sustained increase in the TDE is projected to reduce adult smoking prevalence to 6% in 
2035, from 10% in a baseline scenario. After increasing the TDE, only 65% of female and 
60% of male would-be smokers would actually be smoking in 2035. The intervention is 
projected to avoid around 75,200 new cases of smoking-related diseases between 2015-2035. 
In 2035 alone, £49m in NHS and social care costs and £192m in societal premature mortality 
and morbidity costs is projected to be avoided. 
Conclusion 
Increasing the UK TDE to 5% above inflation could effectively reduce smoking prevalence, 
prevent diseases, and avoid healthcare costs. It would deliver substantial progress towards a 
tobacco-free society, and should be implemented by the UK Government with urgency.  
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INTRODUCTION 
At 219% of the EU average, the UK price level index (PLI) of tobacco is the highest 
among EU member states.[1] The tobacco tax in the UK is currently paid through a 
combination of specific duty (a price per quantity of product, £3.93 per pack of 20 cigarettes 
in 2016), ad valorem duty (a percentage of the retail price, 16.5% in 2016), and a standard 
rate of 20% value-added tax (VAT).[2] The two main products in the UK tobacco market are 
cigarettes and hand-rolled tobacco (HR-T), and separate duties are paid for each. Recent UK 
policies include a minimum excise tax to establish a base rate of tax per pack of cigarettes 
which impacts on the cheapest available options[3] and increased duty on HR-T. Both 
policies are likely to discourage ‘downtrading’ to cheaper tobacco products.[4]  
Over the last 25 years, a notable UK policy has been a duty escalator on cigarettes 
that rises above consumer price inflation, continuously increasing the price of cigarettes.[5]  
This measure is unique among developed economies. In 1991, the Chancellor of the 
Exchequer found “strong arguments for a big duty increase on tobacco”,[6] which followed 
in 1992/93. A duty escalator above inflation was implemented in certain years up to 2001, 
including at 5% above inflation from 1997-2001, before being scrapped and subsequently re-
introduced in 2010. Since then the duty escalator has been set at 2% above inflation, other 
than one year of increase to 5% above inflation in 2012-13. 
Simulation models can inform fiscal policies, predict the impact of tobacco taxation 
on smoking prevalence, disease and economic burdens, and disaggregate the impact of a tax 
from other tobacco control interventions. To date, simulation modelling has typically 
quantified the impact of decreasing smoking prevalence on disease and economic 
outcomes.[7-15] There are fewer examples of estimating the impact of specific taxation 
policies on public health and economic outcomes. Particular countries have implemented 
significant rises in tobacco excise taxes and modelled or evaluated outcomes, including New 
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Zealand[12, 16-18] and Australia,[19] where 12.5% tobacco excise increases are planned 
until 2020. Other recent international examples include Lebanon and Greece.[20, 21] 
Our study estimated the impact of increasing the TDE on cigarettes and HR-T from 
2% to 5% above inflation each year from 2015 to 2035 in the UK, against a natural 
progression baseline scenario based on projections of current and historical smoking 
prevalence and evaluated the impact on disease burden and resulting costs to the UK National 
Health Service (NHS), social care and society.  
METHODS 
Statistical analysis: The UKHF Microsimulation Model 
A dual-module modelling process written in C++ software, is described in depth in 
Supplementary File 1 and Hunt et al,[15] was used for this study. The year 2015 was chosen 
as the start year since the analysis was carried out in 2015. The year 2035 was selected since 
a policy of interest in the UK tobacco control community is the Government establishing a 
‘tobacco-free ambition’ of 5% smoking prevalence or less by 2035.[22] 
Data sources 
The literature was searched for the most recent incidence, prevalence, mortality, 
survival, and relative risk data. Model data inputs including epidemiological parameters  
disease cost data drawn from NHS programme budget costs,[23] and references are presented 
in the supplementary online material.  
Table 1. Data inputs 
Risk Factor data 
1. Historical and current prevalence of smoker status (never smoker, ex-smoker and 
smoker) by age, sex and income quintile 
Disease data 
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2. Most recent incidence, mortality and survival of the diseases of interest, by age and 
sex 
3. Relative risk of acquiring the diseases of interest, by age and sex 
Demographic data 
4. Most recent UK population, by age and sex 
5. Most recent mortality and fertility rates of the UK population 
Health economic data 
6. Mean utility weights of the diseases of interest without medical intervention 
7. Most recent direct NHS costs associated with the diseases of interest 
8. Most recent indirect societal costs associated with the diseases of interest 
Tobacco duty escalator assumptions 
9. Overall average retail price of cigarettes: £7.13(24) 
10. Price of HR-T: £7.89(25) 
11. Price elasticity: -0.5 for cigarettes, and -1.17 for HR-T(26) 
12. Consumer price index: 2% 
13. Level of taxation:  
 VAT at 20%; 
 ad valorem duty at 16.5%;  
 specific duty would increase from £176.20 per 1,000 cigarettes in 2013(25) 
14. Pass on rate: 100% 
15. Illicit trade: 10% of the total market 
 
The model included 14 different smoking-related cancers classified by the 
International Agency for Research on Cancer.[27] 
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These are acute myelogenous leukaemia (AML), bladder, cervical, chronic 
myelogenous leukaemia (CML), colorectal, gallbladder, kidney, laryngeal, liver, lung, 
oesophageal, oral, ovarian, pancreatic. It also included Coronary Heart Disease (CHD), 
Chronic Obstructive Pulmonary Disease (COPD) and stroke.   
Table 1 and the supplementary file 5 provide detail of the assumptions used in the 
TDE scenario. To note, as well as average retail price, the prices of the two tobacco products 
were further defined by the rate of consumer price inflation, level of taxation, the ‘pass-on’ 
rate, and illicit trade. Assumptions on UK tobacco taxation levels and size of the illicit 
tobacco market were based on existing policies and the most recently available data at the 
time of data collection.[28] It was estimated that the illicit tobacco market would remain 
stable at 10% of the total market. The illicit price of tobacco in the UK is estimated to be 50% 
of the legal price,[13] so the illicit price of both cigarettes and HR-T was modelled as such.  
A sensitivity analysis was carried out on the price elasticity for cigarettes to explore 
the impact of this on later outcomes (supplementary file 6).  
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RESULTS 
Increasing and sustaining the TDE in the UK would increase the price of cigarettes by 
87.6% and HR-T products by 78.2% in 2035 relative to the baseline continuation of the 2% 
duty escalator, as displayed in Table 2. This results in an average price of £17.38 per pack of 
20 cigarettes and £15.57 of HR-T products in 2035.  
Table 2.  Predicted impact of the tobacco duty escalator in the baseline and intervention 
scenario on the future price of cigarette products and hand-rolled tobacco (HR-T) between 
2015 and 2035 
 
Cigarettes Hand-rolled tobacco (HR-T) 
Average price in 
baseline scenario 
Average price in 
intervention 
scenario 
Average price in 
baseline scenario 
Average price in 
intervention 
scenario 
2015 £7.05 £7.36 £6.61 £6.87 
2020 £7.78 £9.07 £7.30 £8.37 
2025 £8.59 £11.23 £8.06 £10.26 
2030 £9.48 £13.95 £8.89 £12.61 
2035 £10.47 £17.38 £9.82 £15.57 
 
Over the full course of the simulation period, the prevalence of UK adult smokers in 
the baseline scenario is predicted to decline slowly but consistently based on previous trends, 
reaching 10.0% in 2035 for both men and women (Error! Reference source not found.). 
Supplementary appendix 7 illustrates baseline trends by socioeconomic gradient.  
 
Increasing the TDE would deliver a clear additional impact on decreasing smoking 
prevalence relative to baseline, with this trend sustained throughout the intervention period. 
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Table 3 demonstrates the impact on male and female smoking prevalence in five-year time 
periods. In just 5 years, smoking prevalence is predicted to fall an additional 0.8% for women 
(from 15.0% to 14.2%) and 0.9% for men (16.0 to 15.1%). By 2025, smoking prevalence is 
predicted to fall an additional 1.6% for women (13.0% to 11.4%) and 2.0% for men (14.0% 
to 12.1%). This rate of decline increases further to 2035, where 6.0% of men and 6.5% of 
women smoke compared to 10.0% for both in the baseline.  
Table 3.  Projected baseline and intervention future trends of smoking prevalence in the 
UK between 2015 and 2035 
 
Baseline continuation of 
duty escalator at 2% 
above inflation 
Intervention increasing the tobacco duty escalator 
at 5% above inflation 
Smoking 
Prevalence 
% (All 
female, 18-
100) 
Smoking 
Prevalence 
% (All 
male, 18-
100) 
Smoking 
Prevalence 
% (All 
female, 18-
100) 
Smoking 
Prevalence 
% (All 
male, 18-
100) 
Relative 
reduction 
in smoking 
prevalence 
% (All 
female, 18-
100) 
Relative 
reduction 
in smoking 
prevalence 
% (All 
male, 18-
100) 
2015 17.0 18.0 16.2 16.8 4.8 6.7 
2020 15.0 16.0 14.2 15.1 5.3 5.9 
2025 13.0 14.0 11.4 12.1 12.5 13.9 
2030 11.0 12.0 8.6 9.0 22.2 24.8 
2035 10.0 10.0 6.5 6.0 35.4 39.6 
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An alternative way to consider these results is the proportion of would-be smokers 
who would still be smoking after the intervention, by comparing the impact of the 
intervention on smoking prevalence against the baseline. For example, increasing the duty 
escalator between 2015 and 2025 would mean that only 87.6% of would-be female smokers 
and 86.1% of would-be male smokers are predicted to still be smoking. This impact increases 
over time, so that by 2035 only 64.6% of would-be female smokers and 60.4% of would-be 
male smokers would still be smoking.   
Increasing the TDE was estimated to lead to a modest reduction in the disease burden 
over the time period, avoiding around 7,267 (1.6% of total) new cases of smoking-related 
disease in the year 2035 alone. The majority are cancers (2,907; 1.5%), predominantly lung 
cancers (2,180; 3.7%), followed by COPD (2,180; 3.3%) and stroke (2,180; 2.5%), with no 
significant change recorded for rates of CHD. These data are presented in Table 4, alongside 
the aggregate impact over a 20-year period. Over this time, increasing the TDE is predicted to 
avoid around 75,254 cumulative incident cases of disease in the UK. Supplementary file 8 
presents the incidence and cumulative incidence cases every 5 years of the simulation.  
Increasing the TDE is predicted to avoid £49m in direct NHS and social care costs in 
the year 2035 alone, mostly as a result of fewer cancer cases (£25m). The intervention could 
deliver savings of around £192m in non-health care costs in the year 2035 alone
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Table 4. Increasing the tobacco duty escalator versus a baseline projection, health and economic outcomes by disease. All data is for the UK population in 2035, except the cumulative incidence which is 2015-
2035.   
Tobacco-related disease Baseline  incidence 
(95%CI) 
TDE scenario 
incidence  (95%CI) 
Incidence cases 
avoidable 
(95%CI)  
Baseline cumulative 
incidence (95%CI) 
TDE scenario cumulative 
incidence  (95%CI) 
Cumulative 
incidence cases 
avoidable (95%CI) 
Direct costs  
avoided 
(95%CI) 
/£million 
Coronary Heart Disease (CHD) 99552 (98825-100279) 99552 (98825-
100279) 
0 (-727-727) 1961426 (1959355-
1963497) 
1957284 (1955212-
1959355) 
4142 (1380-6904) 5 (2-8) 
Chronic Obstructive Pulmonary 
Disease (COPD) 
65399 (64672-66126) 63219 (62492-63946)  2180 (1453-2907) 1494025 (1491954-
1496096) 
1474004 (1471932-
1476075) 
20022 (17260-22784) 9 (8-10) 
Stroke 85745 (85018-86472) 83566 (82839-84292)  2180 (1453-2907) 1837844 (1835773-
1839915) 
1817823 (1815752-
1819894) 
20022 (17260-22784) 10 (8-12) 
Smoking-related cancers 196197 (195169-197225) 193291 (192564-
194017)  
2907 (1879-3935) 4290145 (4286763-
4293527) 
4259077 (4255694-
4262459) 
31068 (26926-35210) 25 (18-32) 
Acute Myeloid Leukaemia 
(AML) 
3633 (3633-3633) 3633 (3633-3633) 0 (0-0) 67659 (66969-68349) 67659 (66969-68349) 0 (-690-690) 13 (7-19) 
Bladder Cancer 13080 (13080-13080) 13080 (13080-13080) 0 (0-0) 289968 (289278-290658) 288587 (287897-289278) 1381 (691-2071) 0 (0-0) 
Bowel Cancer 49413 (48686-50140) 49413 (48686-50139) 0 (-727-727) 956894 (955513-958275) 956204 (954823-957585) 690 (-1381-2761) 0 (-2-2) 
Cervical Cancer 3633 (3633-3633) 3633 (3633-3633) 0 (0-0) 69730 (69040-70420) 69730 (69040-70420) 0 (-690-690) 0 (0-0) 
Chronic Myeloid Leukaemia 
(CML) 
727 (727-727) 727 (727-727) 0 (0-0) 15879 (15879-15879) 15879 (15879-15879) 0 (0-0) 0 (0-0) 
Gastric Cancer 8720 (8720-8720) 8720 (8720-8720) 0 (0-0) 176052 (175362-176742) 175362 (174671-176052) 690 (0-1380) 0 (-1-1) 
Hepatic Cancer 5087 (5087-5087) 5087 (5087-5087) 0 (0-0) 106322 (105632-107012) 105631 (104941-106322) 690 (0-1380) 0 (-1-1) 
Laryngeal Cancer 2907 (2907-2907) 2907 (2907-2907) 0 (0-0) 69730 (69040-70420) 69040 (68350-69730) 690 (0-1380) 1 (1-1) 
Lung Cancer 58859 (58132-59586) 56679 (55953-57406)  2180 (1453-2907) 1427056 (1424985-
1429127) 
1410487 (1408416-
1412558) 
16570 (13808-19332) 8 (7-9) 
Oesophageal Cancer 10900 (10900-10900) 10900 (10900-10900) 0 (0-0) 272708 (272018-273398) 269256 (268566-269946) 3452 (2762-4142) 2 (1-3) 
Oral Cancer 7993 (7993-7993) 7993 (7993-7993) 0 (0-0) 194002 (193312-194692) 190550 (189860-191241) 3452 (2762-4142) 1 (1-1) 
Ovarian Cancer 8720 (8720-8720) 8720 (8720-8720) 0 (0-0) 176742 (176052-177432) 175362 (174671-176052) 1381 (691-2071) 1 (0-2) 
Pancreatic Cancer 10900 (10900-10900) 10173 (10173 -10173) 727 (727-727) 220928 (220238-221618) 219547 (218857-220238) 1381 (691-2071) 0 (-2-2) 
Renal Cancer 11627 (11627-11627) 11627 (11627-11627) 0 (0-0) 246473 (245783-247163) 245782 (245092-246473) 690 (0-1380) 0 (0-0) 
Total   446,894 (445,268-
448,519) 
439,627 (438,002-
441,253) 
7,267 (5,642-
8,891) 
9,583,440 (9,578,510-
9,588,371) 
9,508,187 (9,503,256-
9,513,117) 
75,254 (68,926-
81,581) 
49 (40-57) 
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DISCUSSION 
This study finds substantial benefits of increasing the TDE. While benefits begin to 
appear within a five-year period, equivalent to one UK Parliamentary term, it could also 
deliver substantial progress towards achieving a tobacco-free ambition. As a consequence, 
findings show that increasing the TDE could avoid new cases of disease, as well as avoid 
substantial costs to the NHS and wider society. 
This impact could be further maximised by allocating the costs avoided or revenue 
raised to support tobacco control. Using a recent estimate by Claxton et al,[29] investing the 
£49m of direct health costs avoided in this study elsewhere in the NHS would generate the 
equivalent of 1,923 Quality Adjusted Life Years (QALYs), additional to health gains directly 
attributable to the intervention.  
One recurrent tobacco industry claim against increased taxation is its impact on illicit 
trade. While ongoing support to enforce protections against tobacco smuggling is required to 
underpin successful taxation policy, research has found industry claims inconsistent with 
independent data.(30) Substantial progress has been made in the UK with illicit trade rates 
having halved since 2000-01.[28, 31] In addition, a European assessment found the supply of 
illicit tobacco, rather than its price, is a key factor contributing to tax evasion.[32] 
The findings of this study demonstrate the importance of effective tobacco tax policy 
in improving health as well as yielding economic benefits. They strengthen the case that, 
adequately supported with measures to tackle illicit tobacco, increasing the TDE can 
effectively reduce the disease and economic burden caused by smoking in the UK. 
Limitations and future work  
This study has a number of limitations. First, it was not able to account for recent 
policy developments. In particular, the UK Government’s 2016 commitment to a one-off 3% 
increase in duty on HR-T has not been captured in this research.[33] However, this study also 
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modelled the increase in duty of cigarettes and HR-T both by 5% above inflation annually. In 
reality, this calculation would not resolve existing disparity in duty between the tobacco 
products, given a lower baseline duty on HR-T. In another discrepancy between products, the 
rate of illicit trade for cigarettes was also applied to HR-T products in the model, despite data 
suggesting higher rates of illicit trade for these products in the UK. Further, research shows 
that use of HR-T has increased over recent years.[34] Future work will be able to explore the 
impact of this recent, additional increase in duty on the prevalence of HR-T use, and other 
policy mechanisms to address HR-T use such as a tax based on the minimum consumption of 
tobacco products.   
We assumed that the ad valorem rate of duty stayed fixed, which may in the future be 
hindered by European rules which fix a maximum proportion of overall tobacco tax that can 
be from specific duty, , which will have implications for our study on other countries. Future 
work might explain the impact that this will have on later outcomes.  
Since this study only calculated data to 2035, and given the time lag between reducing 
smoking prevalence and decreased risk of developing cancer, these projections will not have 
captured all cases of disease avoided, nor economic burdens prevented, as a result of the 
intervention. In addition, not all diseases caused or exacerbated by smoking were included in 
the model, such as type 2 diabetes mellitus. As such, findings are likely to underestimate the 
total impact of the TDE across the life course.  
While this research assumed a pass-through rate of 100%, emerging research has 
found the tobacco industry may over-shift prices in brand segments other than ultra-low price 
cigarettes. There is evidence from the United Kingdom,[35] United States[36] and New 
Zealand[37] indicating that tobacco prices increase differently across product categories after 
taxation. Ongoing research is required to simulate the complexities of tobacco industry 
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pricing strategies, and encourage more sophisticated responses from governments that 
mitigate against ‘down-trading’ to cheaper tobacco products. 
This study also did not calculate the impact of increasing the TDE on smoking 
prevalence amongst more deprived groups, as disease outputs were not available. However, 
with higher smoking prevalence in the UK (as in many other countries) among those in 
routine and manual professions, compared to professional and managerial roles,[38] it is 
reasonable to assume the benefit of reducing prevalence from a TDE would be 
disproportionately seen in groups of higher smoking prevalence. 
At the time of analysis only smoking prevalence data to 2012 were available. 
Subsequent to that we have observed further declines in smoking prevalence (in line with our 
predictions). Therefore, the results are not a full reflection of the number of disease cases that 
could be avoided if the intervention was introduced in 2017, nor the full time-scale of all 
disease that could occur across a person’s lifetime.  
While data intensive, a review by the OECD deemed the microsimulation method the 
most suitable for risk factor and chronic disease modelling, and is a strength of this study.[39] 
However, as with any model a number of assumptions have to be made, which may lead to 
different sets of results. We used the most robust data inputs available, and validated 
assumptions using both expert opinion and the literature. We carried out a sensitivity analysis 
on the price elasticity (supplementary file 6) where small changes were observed in the 
disease outcomes over time. Unfortunately, it was not possible to carry out a full stochastic 
sensitivity analysis given the many thousands of calculations and parameters within the 
microsimulation, and the necessity of super computers. However, our future work will use a 
variance based method (Sobol’s indices method) on a deterministic model (Jaccard et al, 
forthcoming). 
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The model includes a number of risk factors and a functionality to run multiple risks, 
and has been utilised in over 70 countries.[40-44] However, certain inputs were not included 
that should be considered in future work, either because data are lacking or it was not within 
the scope of the study. Examples include: cross-price elasticity figures of illicit tobacco 
products; elasticity figures for tobacco products stratified by socio-economic class; cross-
elasticities between smoking, drinking and other behavioural risk factors; pass-on rates for 
tobacco products; and recent price elasticity of demand figures. The proportion of smokers 
using cigarettes and HR-T was kept constant throughout the intervention, because of an 
absence of evidence calculating the cross-price elasticities between tobacco products. 
Similarly, this study did not explore the impact of other lower priced alternatives, such as e-
cigarettes, in the market on the effectiveness of increased taxation on smoking.  
In relation to costs, price discounting was not included in calculations in the model. It 
also did not assess the impact of increasing the TDE on revenue collection through tax 
receipts. Indirect cost calculations only explored those resulting from indirect morbidity and 
mortality and not the full range of harms of smoking to society, such as passive smoking, 
domestic fires or litter.  
To inform taxation policy, future research could: include a scenario analysis to 
compensate for different levels of taxation mechanisms or a different time horizon; could 
calculate the revenue generated; predict the negative implications of decreasing tobacco 
taxation on health outcomes;[45] and incorporate years of life saved through policy 
interventions. If conducted in countries where a subsidised or nationalised health system 
(such as the NHS) is not accessible by all, future research should consider the informal costs 
of treating a tobacco-related disease to the individual and family.  
 
Figure legends:  
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Figure 1: Smoking prevalence by sex from 2015 to 2035 for baseline and TDE scenarios. 
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